Daniel Yrigoyen - Arch Therapeutics VP Sales
| ARTH Stock | USD 0.21 0.01 5.00% |
Insider
Daniel Yrigoyen is VP Sales of Arch Therapeutics
| Age | 53 |
| Phone | 617 431 2313 |
| Web | https://www.archtherapeutics.com |
Arch Therapeutics Management Efficiency
The company has return on total asset (ROA) of (1.1363) % which means that it has lost $1.1363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (40.148) %, meaning that it created substantial loss on money invested by shareholders. Arch Therapeutics' management efficiency ratios could be used to measure how well Arch Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Yiftach Roth | Brainsway | 53 | |
| Rajiv Silva | Venus Concept | 57 | |
| Robert Moccia | STRATA Skin Sciences | 65 | |
| William MBA | STRATA Skin Sciences | 58 | |
| Moria Ankri | Brainsway | 40 | |
| Blake Gurfein | Tivic Health Systems | 40 | |
| Naum Muchnik | Icecure Medical | 48 | |
| Richard Ginn | Tenon Medical | 58 | |
| Avner Hagai | Brainsway | 68 | |
| Darrell Rigel | STRATA Skin Sciences | 73 | |
| Michael Goodman | STRATA Skin Sciences | N/A | |
| Soren Sinay | Venus Concept | 53 | |
| Aron Tendler | Brainsway | N/A | |
| Jennifer Ernst | Tivic Health Systems | 56 | |
| John Wilson | Rapid Micro Biosystems | 56 | |
| Pr Zangen | Brainsway | 54 | |
| Domenic Penna | Venus Concept | 62 | |
| Ronen CPA | Icecure Medical | 55 | |
| Sanjay Ahuja | Tivic Health Systems | N/A | |
| Shunichi Kuroda | Bone Biologics Corp | N/A | |
| Eyal Shamir | Icecure Medical | 63 | |
Management Performance
| Return On Equity | -40.15 | |||
| Return On Asset | -1.14 |
Arch Therapeutics Leadership Team
Elected by the shareholders, the Arch Therapeutics' board of directors comprises two types of representatives: Arch Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arch. The board's role is to monitor Arch Therapeutics' management team and ensure that shareholders' interests are well served. Arch Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arch Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Abrams, Chief Officer | ||
| Daniel Yrigoyen, VP Sales | ||
| Terrence MD, Chairman, CoFounder | ||
| Daniel Wadsworth, Advisor Commercialization | ||
| Steven Kates, VP Technology | ||
| Rutledge EllisBehnke, CoFounder Advisor |
Arch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Arch Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -40.15 | |||
| Return On Asset | -1.14 | |||
| Operating Margin | (364.73) % | |||
| Current Valuation | 12.54 M | |||
| Shares Outstanding | 249.94 M | |||
| Shares Owned By Insiders | 14.58 % | |||
| Price To Earning | (16.36) X | |||
| Price To Book | 34.61 X | |||
| Price To Sales | 638.65 X | |||
| Revenue | 15.65 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Arch OTC Stock
Arch Therapeutics financial ratios help investors to determine whether Arch OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arch with respect to the benefits of owning Arch Therapeutics security.